Compare Stocks: LYEL, INBX, GLUE, and IMTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$14.92 -3.0%	$20.30	$4.30 ▼ $25.77	$1.28B	1.59	1.38 million shs	535,896 shs
IMTX Immatics	$8.97 -3.0%	$9.49	$5.05 ▼ $12.41	$1.21B	1.33	452,753 shs	271,415 shs
INBX Inhibrx Biosciences	$91.74 -0.3%	$90.93	$22.40 ▼ $155.29	$1.35B	3.51	312,717 shs	198,079 shs
LYEL Lyell Immunopharma	$14.69 +8.4%	$13.50	$10.49 ▼ $45.00	$359.66M	-0.04	129,717 shs	174,709 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-0.77%	-2.78%	-37.38%	-12.55%	+235.81%
IMTX Immatics	-2.01%	-4.84%	-3.55%	-13.55%	+46.13%
INBX Inhibrx Biosciences	+4.12%	-1.18%	+5.29%	-15.98%	+294.38%
LYEL Lyell Immunopharma	-2.87%	-5.44%	+1.73%	-16.00%	+28.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$14.92 -3.0%	$20.30	$4.30 ▼ $25.77	$1.28B	1.59	1.38 million shs	535,896 shs
IMTX Immatics	$8.97 -3.0%	$9.49	$5.05 ▼ $12.41	$1.21B	1.33	452,753 shs	271,415 shs
INBX Inhibrx Biosciences	$91.74 -0.3%	$90.93	$22.40 ▼ $155.29	$1.35B	3.51	312,717 shs	198,079 shs
LYEL Lyell Immunopharma	$14.69 +8.4%	$13.50	$10.49 ▼ $45.00	$359.66M	-0.04	129,717 shs	174,709 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	-0.77%	-2.78%	-37.38%	-12.55%	+235.81%
IMTX Immatics	-2.01%	-4.84%	-3.55%	-13.55%	+46.13%
INBX Inhibrx Biosciences	+4.12%	-1.18%	+5.29%	-15.98%	+294.38%
LYEL Lyell Immunopharma	-2.87%	-5.44%	+1.73%	-16.00%	+28.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$28.50	91.06% Upside
IMTX Immatics	2.63	Moderate Buy	$20.80	131.91% Upside
INBX Inhibrx Biosciences	2.33	Hold	$150.00	63.51% Upside
LYEL Lyell Immunopharma	2.78	Moderate Buy	$40.86	178.17% Upside

Current Analyst Ratings Breakdown

Latest LYEL, INBX, GLUE, and IMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	LYEL Lyell Immunopharma	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$34.00
8/14/2026	LYEL Lyell Immunopharma	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/11/2026	GLUE Monte Rosa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/7/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $28.00
8/7/2026	GLUE Monte Rosa Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$31.00 ➝ $27.00
8/7/2026	GLUE Monte Rosa Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$29.00 ➝ $27.00
8/6/2026	LYEL Lyell Immunopharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$36.00
8/4/2026	GLUE Monte Rosa Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/3/2026	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$37.00 ➝ $27.00
7/28/2026	GLUE Monte Rosa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
7/27/2026	GLUE Monte Rosa Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLUE Monte Rosa Therapeutics	$123.67M	10.29	N/A	N/A	$3.58 per share	4.17
IMTX Immatics	$37.30M	32.24	N/A	N/A	$4.09 per share	2.19
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	$0.55 per share	N/A
LYEL Lyell Immunopharma	$40K	8,996.40	N/A	N/A	$11.68 per share	1.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
IMTX Immatics	-$222.26M	-$1.99	N/A	N/A	N/A	-572.35%	-47.36%	-39.35%	8/19/2026 (Estimated)
INBX Inhibrx Biosciences	-$140.05M	-$8.88	N/A	N/A	N/A	N/A	-563.90%	-83.48%	N/A
LYEL Lyell Immunopharma	-$274.45M	-$12.83	N/A	N/A	N/A	-920,285.25%	-91.62%	-70.50%	N/A

Latest LYEL, INBX, GLUE, and IMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/18/2026	Q2 2026	IMTX Immatics	-$0.43	-$0.53	-$0.10	-$0.53	$11.90 million	N/A
8/13/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	-$2.34	-$0.06	-$2.34	N/A	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/6/2026	Q2 2026	LYEL Lyell Immunopharma	-$1.94	-$1.9180	+$0.0220	-$1.92	$0.00 million	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
IMTX Immatics	N/A	8.78	8.78
INBX Inhibrx Biosciences	12.58	5.07	5.07
LYEL Lyell Immunopharma	N/A	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLUE Monte Rosa Therapeutics	79.96%
IMTX Immatics	64.41%
INBX Inhibrx Biosciences	82.46%
LYEL Lyell Immunopharma	66.05%

Insider Ownership

Company	Insider Ownership
GLUE Monte Rosa Therapeutics	6.40%
IMTX Immatics	3.30%
INBX Inhibrx Biosciences	18.26%
LYEL Lyell Immunopharma	6.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLUE Monte Rosa Therapeutics	90	85.31 million	79.85 million	Optionable
IMTX Immatics	260	134.07 million	N/A	Optionable
INBX Inhibrx Biosciences	166	14.67 million	11.99 million	Optionable
LYEL Lyell Immunopharma	270	24.50 million	22.99 million	Optionable

LYEL, INBX, GLUE, and IMTX Headlines

Recent News About These Companies

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages

August 13, 2026 | marketbeat.com

Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL

August 11, 2026 | marketbeat.com

Lyell Immunopharma (NASDAQ:LYEL) Research Coverage Started at Stifel Nicolaus

August 9, 2026 | americanbankingnews.com

Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS

August 8, 2026 | marketbeat.com

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

August 7, 2026 | finance.yahoo.com

Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus

August 6, 2026 | marketbeat.com

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday

August 4, 2026 | marketbeat.com

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives $43.00 Consensus Price Target from Analysts

July 22, 2026 | defenseworld.netD

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Consensus Rating of "Moderate Buy" by Brokerages

July 19, 2026 | marketbeat.com

Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet

July 2, 2026 | zacks.com

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual ...

June 26, 2026 | enidnews.comE

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 25, 2026 | globenewswire.com

Lyell Immunopharma Shareholders Back Governance at 2026 Meeting

June 15, 2026 | tipranks.com

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European ...

June 14, 2026 | finance.yahoo.com

New Safety Data and Translational Findings for Ronde-cel in Relapsed or Refractory Large B-Cell Lymphoma Announced by Lyell Immunopharma

June 12, 2026 | quiverquant.comQ

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress

June 12, 2026 | globenewswire.com

Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) Insider Sells 1,977 Shares of Stock

June 12, 2026 | insidertrades.com

Lyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 10, 2026 | seekingalpha.com

Is Lyell Immunopharma (NASDAQ:LYEL) In A Good Position To Deliver On Growth Plans?

June 9, 2026 | finance.yahoo.com

Lyell Immunopharma Reports Significant Reduction in Grade ≥ 2 Diarrhea/Colitis in Phase 1 Trial of LYL273 for Metastatic Colorectal Cancer with GI Prophylaxis

June 8, 2026 | quiverquant.comQ

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

June 8, 2026 | globenewswire.com $https://www.globenewswire.com/news-release/2026/06/08/3307886/0/en/lyell-immunopharma-provides-update-on-safety-profile-of-lyl273-in-relapsed-or-refractory-metastatic-colorectal-cancer-and-amends-phase-1-trial-to-phase-1-2-expansion.html$

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, INBX, GLUE, and IMTX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

$14.92 -0.45 (-2.96%)

As of 02:11 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Immatics NASDAQ:IMTX

$8.95 -0.30 (-3.23%)

As of 02:11 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Inhibrx Biosciences NASDAQ:INBX

$91.74 -0.27 (-0.30%)

As of 02:12 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Lyell Immunopharma NASDAQ:LYEL

$14.70 +1.15 (+8.46%)

As of 02:12 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYEL, INBX, GLUE, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LYEL, INBX, GLUE, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYEL, INBX, GLUE, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, INBX, GLUE, and IMTX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

Immatics NASDAQ:IMTX

Inhibrx Biosciences NASDAQ:INBX

Lyell Immunopharma NASDAQ:LYEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYEL, INBX, GLUE, and IMTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LYEL, INBX, GLUE, and IMTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYEL, INBX, GLUE, and IMTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, INBX, GLUE, and IMTX Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

Immatics NASDAQ:IMTX

Inhibrx Biosciences NASDAQ:INBX

Lyell Immunopharma NASDAQ:LYEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools